Revolutionizing short-duration psychedelic therapies for underserved medical conditions

Reunion Neuroscience is a clinical-stage pharmaceutical company advancing safe, rapid-acting, and short-duration therapies for postpartum depression and adjustment disorder in cancer. Their lead asset, RE104, is a serotonergic psychedelic compound engineered to deliver durable clinical efficacy to patients with underserved mental health conditions.